Bromhexine


Concise Prescribing Info
Indications/Uses
As a mucolytic.
Dosage/Direction for Use
Adult : PO As tab/solution: 8-16 mg tid.
Dosage Details
Oral
Mucolytic
Adult: As tab/solution: 8-16 mg tid.
Child: As tab/solution: 2-5 years 4 mg bid; 6-11 years 8 mg tid; ≥12 years Same as adult dose.
Administration
May be taken with or without food.
Special Precautions
Patient with history of peptic ulcer disease, asthma. Severe renal and hepatic impairment. Treatment with a cough medicine in children (especially under 6 years old) should be considered carefully due to potential risks and limited evidence on efficacy. Pregnancy and lactation.
Adverse Reactions
Significant: Rarely, Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN).
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, upper abdominal pain.
General disorders and administration site conditions: Sweating.
Immune system disorders: Angioedema, urticaria, bronchospasm.
Nervous system disorders: Headache, dizziness.
Skin and subcutaneous tissue disorders: Rash, pruritus.
Action
Description: Bromhexine enhances mucus transport by reducing mucus viscosity and by activating the ciliated epithelium (mucociliary clearance). This secretolytic and secretomotor effect in the bronchial tract area relieves cough and facilitates expectoration.
Pharmacokinetics:
Absorption: Rapidly and completely absorbed from the gastrointestinal tract. Bioavailability: Approx 20%. Time to peak plasma concentration: Approx 1 hour.
Distribution: Widely distributed to body tissues. Crosses blood brain-barrier and placenta (small amounts). Plasma protein binding: Approx 95%.
Metabolism: Undergoes extensive hepatic 1st-pass metabolism.
Excretion: Via urine (approx 85-90%, mainly as metabolites). Terminal elimination half-life: 13-40 hours.
Chemical Structure

Chemical Structure Image
Bromhexine

Source: National Center for Biotechnology Information. PubChem Database. Bromhexine, CID=2442, https://pubchem.ncbi.nlm.nih.gov/compound/Bromhexine (accessed on Jan. 21, 2020)

Storage
Store below 25°C.
ATC Classification
R05CB02 - bromhexine ; Belongs to the class of mucolytics. Used in the treatment of wet cough.
References
Anon. Bromhexine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 02/08/2018.

Boehringer Ingelheim NZ Ltd. Bisolvon Chesty Forte Tablets, Oral Solution data sheet 20 September 2017. Medsafe. http://www.medsafe.govt.nz/. Accessed 02/08/2018.

Buckingham R (ed). Bromhexine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/08/2018.

Disclaimer: This information is independently developed by MIMS based on Bromhexine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Axcel Bromhexine
  • Conhexine
  • Vasican
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in